PL2738259T3 - Myszy adam6 - Google Patents

Myszy adam6

Info

Publication number
PL2738259T3
PL2738259T3 PL14154967T PL14154967T PL2738259T3 PL 2738259 T3 PL2738259 T3 PL 2738259T3 PL 14154967 T PL14154967 T PL 14154967T PL 14154967 T PL14154967 T PL 14154967T PL 2738259 T3 PL2738259 T3 PL 2738259T3
Authority
PL
Poland
Prior art keywords
adam6 mice
adam6
mice
Prior art date
Application number
PL14154967T
Other languages
English (en)
Inventor
Lynn Macdonald
Sean Stevens
Andrew J. Murphy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45998616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2738259(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of PL2738259T3 publication Critical patent/PL2738259T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/22—Heating, cooling or ventilating [HVAC] devices the heat being derived otherwise than from the propulsion plant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/3228—Cooling devices using compression characterised by refrigerant circuit configurations
    • B60H1/32281—Cooling devices using compression characterised by refrigerant circuit configurations comprising a single secondary circuit, e.g. at evaporator or condenser side
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/323—Cooling devices using compression characterised by comprising auxiliary or multiple systems, e.g. plurality of evaporators, or by involving auxiliary cooling devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00642—Control systems or circuits; Control members or indication devices for heating, cooling or ventilating devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/00192—Distribution of conditionned air to left and right part of passenger compartment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/002—Distribution of conditionned air to front and rear part of passenger compartment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Thermal Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
PL14154967T 2011-02-25 2012-02-24 Myszy adam6 PL2738259T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161446895P 2011-02-25 2011-02-25
US201161497650P 2011-06-16 2011-06-16
US201261595200P 2012-02-06 2012-02-06
EP14154967.5A EP2738259B1 (en) 2011-02-25 2012-02-24 ADAM6 mice
EP12716101.6A EP2550363B1 (en) 2011-02-25 2012-02-24 Adam6 mice
PCT/US2012/026416 WO2012141798A1 (en) 2011-02-25 2012-02-24 Adam6 mice

Publications (1)

Publication Number Publication Date
PL2738259T3 true PL2738259T3 (pl) 2020-08-24

Family

ID=45998616

Family Applications (5)

Application Number Title Priority Date Filing Date
PL12192727.1T PL2578688T5 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL14154918.8T PL2738258T5 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL12716101T PL2550363T3 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL22156414.9T PL4067496T3 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL14154967T PL2738259T3 (pl) 2011-02-25 2012-02-24 Myszy adam6

Family Applications Before (4)

Application Number Title Priority Date Filing Date
PL12192727.1T PL2578688T5 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL14154918.8T PL2738258T5 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL12716101T PL2550363T3 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL22156414.9T PL4067496T3 (pl) 2011-02-25 2012-02-24 Myszy adam6

Country Status (31)

Country Link
US (12) US8642835B2 (pl)
EP (7) EP2578688B2 (pl)
JP (8) JP2014507137A (pl)
KR (1) KR101387377B1 (pl)
CN (2) CN105861548B (pl)
AU (5) AU2012243291B2 (pl)
BR (1) BR112013021771B1 (pl)
CA (1) CA2820824A1 (pl)
CY (5) CY1116301T1 (pl)
DE (5) DE14176593T1 (pl)
DK (6) DK2578688T4 (pl)
ES (6) ES2758974T5 (pl)
FI (3) FI2738258T4 (pl)
HR (5) HRP20230526T1 (pl)
HU (5) HUE024534T2 (pl)
IL (4) IL226727A (pl)
IN (1) IN2013CN07629A (pl)
LT (4) LT4067496T (pl)
ME (3) ME02106B (pl)
MX (3) MX343009B (pl)
MY (1) MY172713A (pl)
NZ (2) NZ776770A (pl)
PL (5) PL2578688T5 (pl)
PT (5) PT2550363E (pl)
RS (5) RS59929B1 (pl)
RU (2) RU2582261C2 (pl)
SG (4) SG10201913155QA (pl)
SI (5) SI2738259T1 (pl)
SM (5) SMT201900744T1 (pl)
WO (1) WO2012141798A1 (pl)
ZA (1) ZA201305998B (pl)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
AU2003250074B2 (en) 2002-07-18 2010-09-09 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395017A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
CA2580336C (en) 2004-07-22 2016-07-19 Roger Kingdon Craig Vh heavy chain only antibodies, and vh heavy chain only dimer compounds and uses thereof
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
ES2948572T3 (es) 2009-07-08 2023-09-14 Kymab Ltd Modelos de roedores y moléculas terapéuticas
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
ES2547142T5 (es) 2010-02-08 2021-12-09 Regeneron Pharma Cadena ligera común de ratón
IL315833A (en) 2010-08-02 2024-11-01 Regeneron Pharma Mice producing binding proteins containing VL regions
HUE024534T2 (hu) 2011-02-25 2016-01-28 Regeneron Pharma ADAM6 egerek
CA2841376C (en) 2011-07-05 2023-02-28 Duke University N-terminal deleted gp120 immunogens
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
EP2757875B2 (en) * 2011-09-19 2023-03-22 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
WO2013041845A2 (en) 2011-09-19 2013-03-28 Kymab Limited Animals, repertoires & methods
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US10092638B2 (en) 2011-10-03 2018-10-09 Duke University GP120 immunogens and methods inducing neutralizing antibodies to human immunodeficiency virus
US10246509B2 (en) 2011-10-17 2019-04-02 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US20180295821A1 (en) * 2011-12-02 2018-10-18 Kymab Limited Transgenic Animals
SG11201403326VA (en) 2011-12-20 2014-07-30 Regeneron Pharma Humanized light chain mice
WO2013116609A1 (en) * 2012-02-01 2013-08-08 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
EP2825036B1 (en) 2012-03-16 2018-05-02 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
AU2013204581B2 (en) 2012-03-16 2015-06-25 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
RU2664473C2 (ru) 2012-03-16 2018-08-17 Регенерон Фармасьютикалз, Инк. ОТЛИЧНЫЕ ОТ ЧЕЛОВЕКА ЖИВОТНЫЕ, ЭКСПРЕССИРУЮЩИЕ ЧУВСТВИТЕЛЬНЫЕ К pН ПОСЛЕДОВАТЕЛЬНОСТИ ИММУНОГЛОБУЛИНОВ
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
CN120383672A (zh) 2012-04-20 2025-07-29 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
PT3597037T (pt) * 2012-06-12 2021-06-01 Regeneron Pharma Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
WO2014124156A1 (en) 2013-02-06 2014-08-14 Regeneron Pharmaceuticals, Inc. B cell lineage based immunogen design with humanized animals
SMT201800435T1 (it) 2013-02-20 2018-09-13 Regeneron Pharma Animali non umani con sequenze della catena pesante dell’immunoglobulina modificate riferimento incrociato a domande correlate
EP3841876A1 (en) * 2013-03-14 2021-06-30 Erasmus University Medical Center Rotterdam Transgenic mouse for antibody production
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
JP6267986B2 (ja) * 2014-02-13 2018-01-24 株式会社特殊免疫研究所 ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法
BR112016021572A2 (pt) * 2014-03-21 2017-10-03 Regeneron Pharma Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
ES2762640T3 (es) 2014-03-21 2020-05-25 Regeneron Pharma Proteínas VL de unión a antígeno que exhiben diferentes características de unión
RU2017113134A (ru) 2014-09-19 2018-10-19 Регенерон Фармасьютикалз, Инк. Химерные антигенные рецепторы
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
TWI752920B (zh) 2015-10-12 2022-01-21 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
IL302725A (en) 2016-01-13 2023-07-01 Regeneron Pharma Rodents having an engineered heavy chain diversity region
SG11201806427WA (en) 2016-02-16 2018-08-30 Regeneron Pharma Non-human animals having a mutant kynureninase gene
MX2018014172A (es) * 2016-05-20 2019-08-22 Regeneron Pharma Métodos para romper la tolerancia inmunológica usando múltiples arn guías.
CN109640644B (zh) 2016-06-03 2021-10-26 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
WO2017214089A1 (en) * 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
CA3038720A1 (en) 2016-11-04 2018-07-12 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
US11122042B1 (en) 2017-05-12 2021-09-14 F5 Networks, Inc. Methods for dynamically managing user access control and devices thereof
BR112019025888A2 (pt) 2017-06-07 2020-06-30 Regeneron Pharmaceuticals, Inc. polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica
SG11202003044SA (en) 2017-12-05 2020-04-29 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
JP7779653B2 (ja) 2018-02-07 2025-12-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療用タンパク質送達のための方法および組成物
WO2019182751A1 (en) 2018-03-21 2019-09-26 Crystal Bioscience Inc. Transgenic chicken that produces human antibodies
US20210051929A1 (en) 2018-03-24 2021-02-25 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
CA3093850A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
CA3094400A1 (en) 2018-04-06 2019-10-10 Regeneron Pharmaceuticals, Inc. A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia
MY206284A (en) 2018-05-17 2024-12-06 Regeneron Pharma Anti-cd63 antibodies, conjugates, and uses thereof
WO2019240999A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
EP3927832A4 (en) 2019-02-18 2022-11-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS
US11464217B2 (en) 2019-02-22 2022-10-11 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
SG11202111258TA (en) 2019-06-05 2021-11-29 Regeneron Pharma Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
DK3785536T4 (da) * 2019-08-28 2025-10-27 Trianni Inc Adam6-knockin-mus
CN114901678A (zh) 2019-12-02 2022-08-12 瑞泽恩制药公司 肽-mhc ii蛋白构建体及其用途
IL298632A (en) 2020-06-02 2023-01-01 Biocytogen Pharmaceuticals Beijing Co Ltd Non-human animals genetically modified with a common light chain immunoglobulin locus
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
JP2024500399A (ja) 2020-12-16 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化Ｆｃアルファ受容体を発現するマウス
CA3197426A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
IL303868A (en) 2020-12-23 2023-08-01 Regeneron Pharma Nucleic acids encoding anchor-modified antibodies and uses thereof
KR102871709B1 (ko) 2021-04-20 2025-10-17 리제너론 파마슈티칼스 인코포레이티드 아르테민에 대한 인간 항체 및 이의 사용 방법
EP4554977A1 (en) 2022-07-12 2025-05-21 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
CN120677178A (zh) 2023-02-13 2025-09-19 瑞泽恩制药公司 用抗人cacng1抗体治疗肌肉相关病症
CN121039163A (zh) 2023-05-02 2025-11-28 瑞泽恩制药公司 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途
WO2025014533A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Anti-human cacng1 antibody-drug conjugates and uses thereof
WO2025055311A1 (zh) * 2023-09-15 2025-03-20 赛业（苏州）生物科技有限公司 用于制备抗体的基因修饰小鼠及其制备方法
EP4548758A4 (en) * 2023-09-15 2025-11-19 Cyagen Biosciences Suzhou Inc Genetically modified mice for antibody preparation and the method of preparation
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025145264A1 (zh) * 2024-01-02 2025-07-10 江苏集萃药康生物科技股份有限公司 产生人源化抗体的动物模型及其构建方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994012215A1 (en) * 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with l-selectin
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
CN1203922A (zh) * 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
RU10506U1 (ru) 1999-04-08 1999-08-16 Кривулин Виталий Николаевич Ручной культиватор
EP1183344A4 (en) * 1999-05-27 2003-06-25 Human Genome Sciences Inc ADAM POLYNUCLEOTIDES AND POLYPEPTIDES
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
EP1970448A1 (en) * 2001-05-11 2008-09-17 Kirin Pharma Kabushiki Kaisha Human artificial chromosome containting human antibody lambda light chain and non-human animal containting the human artificial chromosome capable of genetic transmission
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
JP4099646B2 (ja) 2002-06-04 2008-06-11 株式会社安川電機 ボイスコイルモータ
AU2003250074B2 (en) 2002-07-18 2010-09-09 Merus N.V. Recombinant production of mixtures of antibodies
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
PL2767161T3 (pl) 2004-10-19 2018-09-28 Regeneron Pharmaceuticals, Inc. Sposób wytwarzania zwierzęcia homozygotycznego pod względem modyfikacji genetycznej
EP1739691B1 (en) 2005-06-30 2008-12-03 Borealis Technology Oy Outer sheath layer for power or communication cable
WO2007117410A2 (en) * 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
KR101711222B1 (ko) * 2008-12-18 2017-02-28 에라스무스 유니버시티 메디컬 센터 로테르담 인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP5399140B2 (ja) * 2009-06-18 2014-01-29 株式会社タイトー モールス信号通信システム
ES2948572T3 (es) * 2009-07-08 2023-09-14 Kymab Ltd Modelos de roedores y moléculas terapéuticas
MY172472A (en) 2009-12-10 2019-11-26 Regeneron Pharma Mice that make heavy chain antibodies
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
ES2547142T5 (es) 2010-02-08 2021-12-09 Regeneron Pharma Cadena ligera común de ratón
CA2802591A1 (en) * 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
HUE024534T2 (hu) 2011-02-25 2016-01-28 Regeneron Pharma ADAM6 egerek
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
US10246509B2 (en) 2011-10-17 2019-04-02 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
GB201118579D0 (en) 2011-10-27 2011-12-07 Micromass Ltd Control of ion populations
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG11201403326VA (en) 2011-12-20 2014-07-30 Regeneron Pharma Humanized light chain mice
PT3597037T (pt) 2012-06-12 2021-06-01 Regeneron Pharma Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito

Also Published As

Publication number Publication date
EP2738259B1 (en) 2019-11-27
IL261243B (en) 2019-08-29
PT2738259T (pt) 2020-02-18
NZ703609A (en) 2016-04-29
RS59661B1 (sr) 2020-01-31
RU2016109443A (ru) 2018-11-26
DK2738259T3 (da) 2020-02-17
IL226727A (en) 2016-08-31
US10072095B2 (en) 2018-09-11
DK2578688T4 (da) 2023-05-08
PL2738258T3 (pl) 2020-08-24
EP2738258A2 (en) 2014-06-04
PT4067496T (pt) 2023-06-07
MY172713A (en) 2019-12-11
PT2578688T (pt) 2019-10-24
US11950578B2 (en) 2024-04-09
DK2738258T4 (da) 2023-05-08
HK1174490A1 (en) 2013-06-14
SG10201913155QA (en) 2020-02-27
DK4067496T3 (da) 2023-06-26
MX343009B (es) 2016-10-21
US20140213773A1 (en) 2014-07-31
RS59413B2 (sr) 2023-06-30
DK2738259T1 (da) 2014-11-24
IL268671B (en) 2020-05-31
EP3744850A1 (en) 2020-12-02
RU2016109443A3 (pl) 2019-07-24
US20150201589A1 (en) 2015-07-23
US20180346599A1 (en) 2018-12-06
RU2013125717A (ru) 2014-12-10
EP2738259A2 (en) 2014-06-04
US8642835B2 (en) 2014-02-04
PL2550363T3 (pl) 2015-05-29
HRP20230526T1 (hr) 2023-09-01
EP2738259A3 (en) 2014-07-30
MX2013009649A (es) 2013-09-26
IL268671A (en) 2019-10-31
DK2738258T3 (da) 2019-12-16
SI2578688T2 (sl) 2023-05-31
JP2014110814A (ja) 2014-06-19
HRP20192311T1 (hr) 2020-03-20
SMT201500061B (it) 2015-05-05
JP5866127B2 (ja) 2016-02-17
JP2022071051A (ja) 2022-05-13
CA2820824A1 (en) 2012-10-18
NZ612643A (en) 2015-06-26
EP2738258B1 (en) 2019-09-25
US10577430B2 (en) 2020-03-03
ES2770424T3 (es) 2020-07-01
NZ776770A (en) 2023-03-31
HRP20191895T4 (hr) 2023-05-12
PT2550363E (pt) 2015-03-16
KR101387377B1 (ko) 2014-04-21
PT2738258T (pt) 2019-12-10
JP2019187446A (ja) 2019-10-31
HUE062552T2 (hu) 2023-11-28
HRP20200294T1 (hr) 2020-05-29
HUE024534T2 (hu) 2016-01-28
LT2738258T (lt) 2020-01-10
ME03537B (pl) 2020-04-20
CY1116301T1 (el) 2017-02-08
US10905108B2 (en) 2021-02-02
ME03732B (me) 2021-01-20
SI2738258T1 (sl) 2020-01-31
AU2015238806A1 (en) 2015-10-29
CY1122820T1 (el) 2021-05-05
PL2738258T5 (pl) 2023-05-15
SI2550363T1 (sl) 2015-04-30
AU2020201279A1 (en) 2020-03-12
LT4067496T (lt) 2023-06-12
CN105861548A (zh) 2016-08-17
AU2017251802A1 (en) 2017-11-16
IL273986A (en) 2020-05-31
US20130254911A1 (en) 2013-09-26
US20240306617A1 (en) 2024-09-19
HRP20191895T1 (hr) 2020-01-10
EP2550363B1 (en) 2014-12-10
EP2550363A1 (en) 2013-01-30
DK2578688T3 (da) 2019-10-28
SG192933A1 (en) 2013-09-30
RS59929B1 (sr) 2020-03-31
ES2748832T5 (es) 2023-06-08
SG10201405135RA (en) 2014-10-30
ES2946169T3 (es) 2023-07-13
RU2722373C2 (ru) 2020-05-29
US9932408B2 (en) 2018-04-03
EP2738258B2 (en) 2023-02-01
FI2578688T4 (fi) 2023-05-05
CN103429746B (zh) 2016-05-11
BR112013021771B1 (pt) 2022-11-16
IL261243A (en) 2018-10-31
RS59413B1 (sr) 2019-11-29
ES2532487T3 (es) 2015-03-27
HUE046746T2 (hu) 2020-03-30
US9944716B2 (en) 2018-04-17
PL4067496T3 (pl) 2023-07-31
AU2022206806B2 (en) 2025-10-02
ES2758974T3 (es) 2020-05-07
HUE046081T2 (hu) 2020-01-28
SI2738258T2 (sl) 2023-05-31
SG10201913160QA (en) 2020-03-30
DK2813573T1 (da) 2015-01-12
DK2738258T1 (da) 2014-11-24
PL2578688T3 (pl) 2020-05-18
LT2578688T (lt) 2019-11-11
EP2738258A3 (en) 2014-09-24
CN103429746A (zh) 2013-12-04
NZ797720A (en) 2024-09-27
ES2805364T3 (es) 2021-02-11
DE12192727T1 (de) 2013-07-11
EP2578688A1 (en) 2013-04-10
RU2582261C2 (ru) 2016-04-20
DE14154967T1 (de) 2014-08-28
IN2013CN07629A (pl) 2015-08-07
AU2012243291B2 (en) 2015-07-09
ES2748832T3 (es) 2020-03-18
SI2738259T1 (sl) 2020-06-30
RS64280B1 (sr) 2023-07-31
PL2578688T5 (pl) 2023-05-29
EP4067496B1 (en) 2023-03-29
LT2738259T (lt) 2020-03-10
NZ731926A (en) 2021-07-30
DE14176593T1 (de) 2015-03-05
SMT202300173T1 (it) 2023-07-20
RS53880B1 (sr) 2015-08-31
US10694725B2 (en) 2020-06-30
DK2550363T3 (en) 2015-03-23
US20210105984A1 (en) 2021-04-15
JP2014507137A (ja) 2014-03-27
AU2012243291A1 (en) 2013-05-09
BR112013021771A2 (pt) 2017-07-04
US10905109B2 (en) 2021-02-02
US20120322108A1 (en) 2012-12-20
HK1201292A1 (en) 2015-08-28
EP2578688B2 (en) 2023-02-08
EP2578688B1 (en) 2019-07-24
DE14154918T1 (de) 2014-08-21
US12207628B2 (en) 2025-01-28
CY1122205T1 (el) 2020-11-25
FI2738258T4 (fi) 2023-05-05
DK4067496T5 (da) 2024-07-22
JP2018143250A (ja) 2018-09-20
NZ718688A (en) 2017-07-28
MX2020009714A (es) 2020-10-07
EP2813573A1 (en) 2014-12-17
ES2758974T5 (es) 2023-06-08
CY1122459T1 (el) 2021-01-27
EP4067496A1 (en) 2022-10-05
CN105861548B (zh) 2020-01-10
EP2813573B1 (en) 2020-04-22
HUE047687T2 (hu) 2020-05-28
SI4067496T1 (sl) 2023-07-31
DK2578688T1 (da) 2014-11-24
US20180345760A1 (en) 2018-12-06
AU2022206806A1 (en) 2022-08-18
HRP20150262T1 (hr) 2015-04-10
ZA201305998B (en) 2016-07-27
KR20130116375A (ko) 2013-10-23
US20180362663A1 (en) 2018-12-20
SMT201900744T1 (it) 2020-01-14
JP2015107131A (ja) 2015-06-11
US20180346598A1 (en) 2018-12-06
HRP20192311T4 (hr) 2023-05-12
US20210105985A1 (en) 2021-04-15
DE12716101T1 (de) 2013-05-08
US20150210776A1 (en) 2015-07-30
WO2012141798A1 (en) 2012-10-18
SI2578688T1 (sl) 2019-11-29
IL273986B (en) 2021-04-29
MX375115B (es) 2025-03-06
JP2016135143A (ja) 2016-07-28
JP2025032218A (ja) 2025-03-11
CY1126091T1 (el) 2023-11-15
SMT202000112T1 (it) 2020-05-08
FI4067496T3 (fi) 2023-05-24
SMT201900581T1 (it) 2019-11-13
RS59661B2 (sr) 2023-06-30
US8697940B2 (en) 2014-04-15
ME02106B (me) 2015-10-20

Similar Documents

Publication Publication Date Title
IL273986B (en) adam6 mice
DK2691417T4 (en) Antistof fc-varianter
AP2014007621A0 (en) 2-Thiopyrimidinones
DK2770906T3 (en) Applanationstonometer
AU339404S (en) Pen
AU5171P (en) Sunparamiho Mandevilla xamabilis
AU4540P (en) BUNNAN Baloskion tetraphyllum
AU5031P (en) BESYS Beschorneria yuccoides
GB201109865D0 (en) Touchiness interaction
AP00723S1 (en) Autorickshaw
AP2011000390S (en) Kuppkraft
AU339857S (en) Orchidometer
AU338110S (en) Barstool
GB201112069D0 (en) Ecowash
AU2011303V (en) Silverado Dianella tasmanica
AU2011035V (en) DBK02 Babingtonia virgata
AU338420S (en) Kettlebell